Year-end Sale % OFF 
Abstract
Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.
Highlights
Streptococcus pneumoniae is a leading cause of disease in children worldwide
An increased occurrence of pneumococcal empyema, due to emerging serotypes, and the continued prominence of serotype 1 as a cause of severe pneumonia post-PCV7 introduction support the added potential benefit of higher valency pneumococcal vaccines to prevent a greater proportion of pneumonia cases, including pneumonia associated with complications
PCV7 has been highly effective in reducing global pneumococcal disease burden
Summary
Streptococcus pneumoniae is a leading cause of disease in children worldwide. Common manifestations of pneumococcal disease include meningitis, bacteremia, pneumonia and otitis media. Introduction and routine infant use of PCV7 resulted in significant reductions of invasive pneumococcal disease (IPD) among vaccinated children. Routine PCV7 use has led to significant decreases in the incidence of pneumococcal disease, due to the seven vaccine types, a substantial proportion of pneumococcal disease burden, due to serotypes not included in PCV7, still exists. The selection of serotypes included in higher valency pneumococcal conjugate vaccines (PCVs) was based on the need for a broader coverage of serotypes that have become more frequent causes of pneumococcal disease following PCV7 immunization, while continuing to maintain protection against disease, due to PCV7 serotypes. (a) changes in the serotype epidemiology of invasive pneumococcal disease (IPD), including complicated pneumonia, prior to and following the introduction of PCV7 and higher valency PCVs;. (b) available post-marketing IPD surveillance data that reflect the direct impact on the vaccinated/vaccine-eligible age group of children following the introduction of higher valency PCVs; and (c) future prospects for the development of new pneumococcal vaccines
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
